14
Participants
Start Date
April 1, 2025
Primary Completion Date
July 1, 2025
Study Completion Date
July 8, 2025
SRW Ndo1
The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).
Baohua, Guangzhou
Wellizen Australia
INDUSTRY